Shanghai Junshi Biosciences

aka Junshi, 君实生物

Junshi developed toripalimab, the first Chinese PD-1 antibody approved in China (2018) and the first approved by the FDA (2023, nasopharyngeal cancer).

Toripalimab (Tuoyi / Loqtorzi) has more than ten NMPA indications, US approval for nasopharyngeal carcinoma with Coherus (licence February 2021, $150 million upfront), and EU, UK and Australian approvals. Pipeline: the BTLA antibody tifcemalimab, a PD-1 x VEGF bispecific and ADCs. Junshi also co-developed the COVID-19 antibody etesevimab with Lilly.

Headquarters

Shanghai, CN

Scorecard

All companies

#55of 680 companies, score 45

approved products +6
targets +2
modalities +2
regions +5
registry trials +30

1 approved, 0 in phase 3, 0 earlier, 1 targets, 541 registry studies. Formula on the scorecards page.

Deals

Deal map

Date	Deal	Type	Upfront	Total	Source
2021-02-01	Shanghai Junshi Biosciences to Coherus BioSciences Toripalimab (Loqtorzi), anti-PD-1 antibody; options on two further programmes	Licence	$150m	up to $1.11bn	source